The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

McDonald’s said Monday it plans to hire up to 375,000 U.S. restaurant employees this summer, its biggest hiring push in years ...

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

If a higher body weight is affecting your ability to get around, or you have joint pain from arthritis, it can impair your ...

Lilly's obesity therapy recently outperformed Wegovy in a head-to-head weight loss study, while CagriSema's top-line efficacy was in the same ballpark as Zepbound in the phase 3 readout.

Only three drugs – Novo Nordisk’s Wegovy and Saxenda, and Eli Lilly’s Zepbound – are actually approved for that purpose. Now, if used correctly, these drugs can be a lifeline for patients.

NBC News medical contributor Dr. Natalie Azar and TODAY nutrition and health expert Joy Bauer stop by Studio 1A to talk about the benefits of the nutrient magnesium and ways you can incorporate it ...